Locus Biosciences
Clinical-stage biotechnology company developing precision bacteriophage-based therapeutics using an automation and AI-driven discovery platform, synthetic biology and GMP manufacturing to address antibiotic-resistant bacterial infections and related indications.
Industries
Nr. of Employees
medium (51-250)
Locus Biosciences
Patents
Products
Investigational CRISPR-enhanced bacteriophage therapy targeting E. coli (clinical-stage)
Clinical-stage investigational bacteriophage cocktail engineered with a CRISPR-based construct to target Escherichia coli, combining phage lytic activity and targeted genomic disruption to treat infections such as urinary tract infections.
LBP-KP01
LBP-KP01 is a precision medicine designed to target K. pneumoniae infections. It is an engineered bacteriophage product to precisely remove K. pneumoniae bacteria in patients with complicated UTls.
LBP-PA01
LBP-PA01 is a precision medicine designed to target P. aeruginosa infections. It is an engineered bacteriophage product to precisely remove P. aeruginosa bacteria in patients with pneumonia.
LBP-EC01
LBP-EC01 is a precision medicine designed to target E. coli infections. It is an engineered bacteriophage product to precisely remove E. coli bacteria in patients with urinary tract infections (UTIs).
SHIELD
Intelligent automation platform that rapidly creates optimized precision therapies using AI-driven combinatorial biochemistry and phage engineering.
LBP-OP01
LBP-OP01 is a precision medicine that targets ophthalmic bacterial infections.
Investigational CRISPR-enhanced bacteriophage therapy targeting E. coli (clinical-stage)
Clinical-stage investigational bacteriophage cocktail engineered with a CRISPR-based construct to target Escherichia coli, combining phage lytic activity and targeted genomic disruption to treat infections such as urinary tract infections.
LBP-KP01
LBP-KP01 is a precision medicine designed to target K. pneumoniae infections. It is an engineered bacteriophage product to precisely remove K. pneumoniae bacteria in patients with complicated UTls.
LBP-PA01
LBP-PA01 is a precision medicine designed to target P. aeruginosa infections. It is an engineered bacteriophage product to precisely remove P. aeruginosa bacteria in patients with pneumonia.
LBP-EC01
LBP-EC01 is a precision medicine designed to target E. coli infections. It is an engineered bacteriophage product to precisely remove E. coli bacteria in patients with urinary tract infections (UTIs).
SHIELD
Intelligent automation platform that rapidly creates optimized precision therapies using AI-driven combinatorial biochemistry and phage engineering.
LBP-OP01
LBP-OP01 is a precision medicine that targets ophthalmic bacterial infections.
Services
Platform services that combine automated laboratory workflows with AI/ML to support surveillance, discovery, cocktail optimization, and development workflows for bacteriophage therapeutics.
Platform services that combine automated laboratory workflows with AI/ML to support surveillance, discovery, cocktail optimization, and development workflows for bacteriophage therapeutics.
Expertise Areas
- Engineered bacteriophage therapeutics
- AI/ML-driven therapeutic discovery
- Clinical development and trial execution for biologics
- GMP biomanufacturing and scale-up
Key Technologies
- CRISPR-Cas nucleic-acid targeting
- Bacteriophage engineering
- Artificial intelligence / machine learning
- Next-generation sequencing and genomic analysis
News & Updates
Reported award of $3.3M from NIH to support a clinical trial of an AI-designed bacteriophage therapy for pneumonia caused by antibiotic-resistant bacteria.
Announcement of a research collaboration to develop precision antibacterial therapies for ophthalmic infections.
Announcement of release of $23.9M under a BARDA contract to support continuation of clinical development of a CRISPR-enhanced bacteriophage therapy for E. coli urinary tract infections, and details on the ELIMINATE Phase 2 study design and Part 1 results.
Reported award of $3.3M from NIH to support a clinical trial of an AI-designed bacteriophage therapy for pneumonia caused by antibiotic-resistant bacteria.
Announcement of a research collaboration to develop precision antibacterial therapies for ophthalmic infections.
Announcement of release of $23.9M under a BARDA contract to support continuation of clinical development of a CRISPR-enhanced bacteriophage therapy for E. coli urinary tract infections, and details on the ELIMINATE Phase 2 study design and Part 1 results.